About Us

Who We Are

Capricor Therapeutics (NASDAQ: CAPR) is a biotechnology company dedicated to advancing transformative cell and exosome-based therapeutics to redefine the treatment landscape for rare diseases. At Capricor, we are committed to pushing the boundaries of possibility and forging a path toward transformative treatments for those in need. At the forefront of our innovation is our lead product candidate, Deramiocel, an allogeneic cardiac-derived cell therapy that is currently in late-stage clinical development for the treatment of Duchenne muscular dystrophy (DMD). Capricor is also leveraging the power of its exosome technology, using its proprietary StealthX™ platform focused on vaccinology and the targeted delivery of oligonucleotides, proteins, and small-molecule therapeutics, with the potential to treat and prevent a wide range of diseases. Our translational approach to product development is based on the strong research foundation provided by our academic partnerships with leading scientists at top-tier research institutions.

Our Portfolio

Capricor’s lead product candidate, Deramiocel is an allogeneic cell therapy comprised of allogeneic cardiosphere-derived cells, or CDCs. The ability of Deramiocel to slow disease progression in Duchenne muscular dystrophy lies in the immunomodulatory, anti-inflammatory and anti-fibrotic actions of CDCs, which are mediated by secreted exosomes containing bioactive cargo. Among the cargo elements known to be bioactive in CDC-exosomes are microRNAs. Collectively, these non-coding RNA species alter gene expression in macrophages and other target cells, dialing down generalized inflammation and stimulating tissue regeneration in DMD. 

Capricor has also established itself as one of the leading companies advancing exosome-based technology. Emerging as an exciting class of potential therapeutic agents and drug delivery vehicles, exosomes are nanosized particles with biologically active contents that are secreted by cells and serve to direct or re-direct the activities of other cells. Capricor is focused on developing a precision-engineered exosome platform technology with the ability to deliver defined sets of effector molecules which exert their effects through defined mechanisms of action. Our StealthX™ exosome platform builds on advances in fundamental RNA and protein science, targeting technology and manufacturing, providing us the opportunity to potentially build a broad pipeline of new therapeutic candidates.

View Our Pipeline